Monoclonal antibody Bebtelovimab neutralizes all isoforms of Omicron variants
- Statins Lower Blood Lipids: How Long is a Course?
- Warning: Smartwatch Blood Sugar Measurement Deemed Dangerous
- Mifepristone: A Safe and Effective Abortion Option Amidst Controversy
- Asbestos Detected in Buildings Damaged in Ukraine: Analyzed by Japanese Company
- New Ocrevus Subcutaneous Injection Therapy Shows Promising Results in Multiple Sclerosis Treatmen
- Dutch Man Infected with COVID-19 for 613 Days Dies: Accumulating Over 50 Virus Mutations
Monoclonal antibody Bebtelovimab neutralizes all isoforms of Omicron variants
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Monoclonal antibody Bebtelovimab neutralizes all isoforms of Omicron variants.
Recently, a research paper on “Antibody evasion properties of SARS-CoV-2 Omicron sublineages” was published in “Nature”.
After experimenting with 19 monoclonal antibodies, the study found that only the bebtelovimab ( LY-COV1404 ) antibody can adequately neutralize all subtypes of the omicron variant .
These findings are part of a recent analysis by the team that showed that the three subtypes of Omicron mutated to the same extent as wild-type SARS-CoV-2 (SARS-CoV-2) and reduced the risk of mRNA vaccines Similar comparability in potency .
After confirming the Omicron BA.1 mutant, the authors continued to monitor two clades where further variants were found: BA.1+ R346K and BA.2 .
The BA.1 + R346K subtype accounts for about 40% of the present global Omicron sequences and 35-60% in New Zealand, the UK and the US.
The BA.2 subtype, which accounts for about 10% of the global Omicron sequence, is increasing in prevalence and has become predominant in Denmark, India, and South Africa.
In addition, the authors investigated the sensitivity of each subtype of Omicron to neutralizing sera from individuals previously infected with wild-type 2019-nCoV (10 individuals), vaccinated with Pfizer-BioNTech (13 individuals), or Modder NA (12 people) vaccine individuals, and individuals who received any of the above mRNA vaccines as booster shots (15 people).
The authors found that the neutralizing activity of serum for BA.1 + R346K and BA.2 subtypes was significantly lower than that of wild-type 2019-nCoV, and the degree of decline was comparable to that of BA.1 previously reported.
However, the reduction in neutralizing activity was less pronounced in the sera of booster-vaccinated individuals.
(Figure 1. BA.2 shows a serum neutralization profile similar to the BA.1 subtype.)
In laboratory experiments against 19 monoclonal antibodies, the authors found that BA.2 was significantly resistant to 17 of them. This includes a 27-fold decrease in the activity of sotrovimab, which retains decent activity against both BA.1 and BA.1 + R246K. Of the other two antibodies, cilgavimab (alone or in combination with tixagevimab) retained activity against BA.2 but was ineffective against BA.1. Only the recently approved bebtelovimab is effective against all three subtypes of Omicron.
(Figure 2. BA.2 has different resistance to monoclonal antibodies)
The team concluded in the paper that the emergence of new coronavirus variants has reduced treatment options, and new strategies must continue to be developed to control the new coronavirus.
Monoclonal antibody Bebtelovimab neutralizes all isoforms of Omicron variants
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
